Back to today’s briefing

Story perspectives

Zorevunersen Cuts Seizures by 50% in Dravet Syndrome Trials

3/5/2026

44 6 Full Breakdown

Summary

Story summary

Zorevunersen reduced seizures by about 50% in early trials for Dravet syndrome.
The study, led by University College London (UCL) and Great Ormond Street Hospital, involved about 3,000 children in the UK.
The findings also indicate improvements in quality of life for participants.
A phase 3 trial will further assess the drug's long-term effects.

1 of 1

Story summary

Zorevunersen reduced seizures by about 50% in early trials for Dravet syndrome.
The study, led by University College London (UCL) and Great Ormond Street Hospital, involved about 3,000 children in the UK.
The findings also indicate improvements in quality of life for participants.
A phase 3 trial will further assess the drug's long-term effects.